Next Generation CART MAD

Next Generation CART MAD consortium was created with the aim of bringing together the knowledge of entities specialized in the study of immunology, immunotherapy, gene and cell therapy and pediatric oncology. Among the main entities included in the consortium we can find the UAM, the CSIC and the most relevant hospitals in Madrid. All of them share a wide experience in the aforementioned areas. The main objectives of the consortium are focused on:

  • To identify, develop and validate new cell engineering approaches applied to effectors of the innate and adaptive immune system for the treatment of refractory neoplasms, especially in pediatrics.
  • To apply the most promising treatments in multicenter clinical trials to evaluate their efficacy.

The experience of the consortium groups allowed the identification of certain weaknesses in current cellular immunotherapy strategies. The consortium aims to promote the development of new generation of therapeutic tools and approaches to offer real clinical solutions. The possibility of combining a living cell platform with the ability to genetically reprogram antitumor behavior generates a therapeutic potential unprecedented. Our goal is to enhance and capitalize on the strengths from each group by creating a multidisciplinary consortium with proven experience in the clinical application of adoptive cell therapies in oncology, especially in oncopediatrics. Starting from basic and preclinical development, the last objective of the consortium is to develop new CAR-T, STAb-T and combined (CAR-STAb-T) therapies, with special emphasis on multitarget strategies; as well as interleukin–based “armored” CAR-T and CAR-NK therapies.

Next Generation CART MAD proposes to use diverse cell lineages and next-generation gene transfer strategies. Our goal is to develop safer, more effective and persistent methods, as well as chimeric antigen receptor combinations to facilitate clinical scale-up of cellular products, a crucial point when transferring results. The interdisciplinary nature of the Consortium, which includes preclinical and clinical groups, will allow the incorporation of different technologies in gene transfer, cell manipulation, preclinical cancer models with poor prognosis, especially childhood cancers, and the production of advanced cellular immunotherapy tools. All this is a guarantee that significant advances will be made in the development of advanced immunotherapies against poor prognosis cancers. This appoach constitutes a compulsory goal for the clinical entities included in the consortium, (Hospital Niño Jesús, Hospital La Paz, Hospital 12 de Octubre, Hospital Fundación Jiménez Díaz, ISCIII and CSIC).

The inclusion of emerging groups and young researchers in the consortium and the participation of biotechnology companies and non-profit foundations will ensure that the knowledge generated has a high social impact and is transferred to the industrial sector. The consortium members provide a multidisciplinary environment that covers all stages of the translational research process, allowing a degree of synergy greater than the sum of its parts. This consortium represents an unprecedented opportunity to lead the field of cellular immunotherapies for childhood cancer in Madrid and in Europe. Our ultimate goal is that during the project and with the therapies developed by the Consortium, at least two “first-in-human” clinical trials can be carried out in patients with refractory cancer